SCHEMBL17024108

SCHEMBL17024108

CC(C)(C)CC(C)(C)c1ccc(OCC(O)[CH]O)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 3/20 0.56
▸ SMN1; SMN2 Q16637 3/20 0.56
▸ SHBG P04278 1/20 0.46
▸ MDH1 P40925 8/20 0.43
▸ MDH2 P40926 8/20 0.43
▸ HIF1A Q16665 5/20 0.41
▸ HTT P42858 3/20 0.41
▸ AR P10275 1/20 0.40
▸ MEN1 O00255 3/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ APAF1 O14727 2/20 0.39
▸ USP2 O75604 2/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ LMNA P02545 2/20 0.39
▸ ERBB2 P04626 2/20 0.39
▸ TP53 P04637 2/20 0.39
▸ FYN P06241 2/20 0.39
▸ CHRM2 P08172 2/20 0.39
▸ CHRM4 P08173 2/20 0.39
▸ CHRM5 P08912 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17024094 0.86 NPC1 (0.45) HIF1AHTTARMAPTTDP1
SCHEMBL17024101 0.84 MAPT (0.50) SMN1; SMN2HIF1AHTTARMEN1
SCHEMBL7879426 0.83 CYP3A4 (0.61) CYP3A4SMN1; SMN2SHBGMDH1MDH2
SCHEMBL15677164 0.80 AR (0.62) CYP3A4SMN1; SMN2SHBGMDH1MDH2
SCHEMBL17024104 0.79 KMT2A (0.55) SMN1; SMN2HIF1AHTTARMEN1
SCHEMBL2108184 0.77 CYP3A4 (0.62) CYP3A4SMN1; SMN2SHBGMDH1MDH2
SCHEMBL2108647 0.77 SMN1; SMN2 (0.54) CYP3A4SMN1; SMN2SHBGMDH1MDH2
SCHEMBL15677151 0.77 SMN1; SMN2 (0.54) CYP3A4SMN1; SMN2SHBGMDH1MDH2
SCHEMBL10612296 0.77 CYP3A4 (0.54) CYP3A4SMN1; SMN2SHBGMDH1MDH2
SCHEMBL10412598 0.75 SMN1; SMN2 (0.60) CYP3A4SMN1; SMN2SHBGMDH1MDH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150238401-A1 PROPYL-PHENYL-ETHER DERIVATIVE, AND MELANOGENESIS INHIBITOR, SKIN-LIGHTENING AGENT, ANTIMICROBIAL AGENT AND COSMETIC CONTAINING SAID PROPYL-PHENYL-ETHER DERIVATIVE SEIWA KASEI COMPANY, LIMITED (JP) 2015-08-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150238401-A1 PROPYL-PHENYL-ETHER DERIVATIVE, AND MELANOGENESIS INHIBITOR, SKIN-LIGHTENING AGENT, ANTIMICROBIAL AGENT AND COSMETIC CONTAINING SAID PROPYL-PHENYL-ETHER DERIVATIVE TYR, MITF, MC1R CYP3A4 815/4885SMN1; SMN2 4407/4885SHBG 2000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback